iBio, Inc. (IBIO)
- GlobeNewswire
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update. “In our third fiscal quarter, we continued to advance toward our goal
- GlobeNewswire
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – B
- GlobeNewswire
iBio Announces $15.0 Million Private Placement
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement
